Published in Immunol Lett on October 01, 1986
Functional analysis of two human T-cell subpopulations: help and suppression of B-cell responses by T cells bearing receptors for IgM or IgG. J Exp Med (1977) 9.57
Detection of extracellular toxin(s) produced by Vibrio vulnificus. Infect Immun (1981) 3.95
Morphological and histochemical analyses of two human T-cell subpopulations bearing receptors for IgM or IgG. J Exp Med (1978) 2.58
Fc-receptor heterogeneity of human suppressor T cells. J Immunol (1978) 2.37
Hepatitis C virus infection and liver disease in blood donors. Br J Hosp Med (1994) 2.04
Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut (2004) 1.93
Raised serum IgG and IgA antibodies to mycobacterial antigens in rheumatoid arthritis. Ann Rheum Dis (1989) 1.85
Detection of immunoglobulin M antibodies to glycoprotein G-2 by western blot (immunoblot) for diagnosis of initial herpes simplex virus type 2 genital infections. J Clin Microbiol (1993) 1.83
Association between MHC class II alleles and clearance of circulating hepatitis C virus. Members of the Trent Hepatitis C Virus Study Group. J Infect Dis (1998) 1.77
Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care (1997) 1.76
Imbalances in T cell subpopulations associated with immunodeficiency and autoimmune syndromes. Eur J Immunol (1977) 1.74
Autoantibodies in chronic hepatitis C virus infection and their association with disease profile. J Viral Hepat (2009) 1.63
Ontogeny of B cells in the chicken. I. Sequential development of clonal diversity in the bursa. J Exp Med (1976) 1.63
HCV and PCR negativity. Lancet (1992) 1.43
Development of a strand-specific RT-PCR based assay to detect the replicative form of hepatitis C virus RNA. J Virol Methods (2001) 1.43
Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study. J Hepatol (2001) 1.42
Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. Eur J Immunol (2001) 1.40
Suppression of B lymphocyte differentiation by newborn T lymphocytes with an Fc receptor for IgM. Clin Exp Immunol (1978) 1.36
Induction of tumor necrosis factor alpha production by adhered human monocytes: a key role for Fcgamma receptor type IIIa in rheumatoid arthritis. Arthritis Rheum (2000) 1.34
Studies of generation of B-cell diversity in mouse, man, and chicken. Cold Spring Harb Symp Quant Biol (1977) 1.30
Idiotypic networks and their possible exploitation for manipulation of the immune response. Lancet (1981) 1.29
Use of the ELISA to screen for anti-thymocyte and anti-beta 2-microglobulin antibodies in leprosy and SLE. Immunology (1980) 1.22
Reduced B-cell galactosyltransferase activity in rheumatoid arthritis. Lancet (1987) 1.21
The reliability of serological tests for the diagnosis of genital herpes: a critique. Pathology (1993) 1.20
Interaction of hepatitis B and hepatitis C infection in haemophilia. Br J Haematol (1993) 1.17
Autoimmunity and idiotypes. Lancet (1984) 1.17
CD5 expression in human B-cell populations. Immunol Today (1999) 1.15
A minority of patients with rheumatoid arthritis show a dominant rearrangement of T-cell receptor beta chain genes in synovial lymphocytes. Scand J Immunol (1987) 1.13
Histamine suppression of lymphocyte activation. Clin Exp Immunol (1980) 1.12
The prevalence and distribution of macrophages bearing Fc gamma R I, Fc gamma R II, and Fc gamma R III in synovium. Scand J Rheumatol (1990) 1.11
Hepatitis C in blood donors. Lancet (1993) 1.10
Characteristics and function of Fc receptors on human lymphocytes. Immunology (1982) 1.09
Surface expression of heat shock protein 90 by blood mononuclear cells from patients with systemic lupus erythematosus. J Autoimmun (1992) 1.08
Pathogenic autoantibodies in the NZB mouse are specific for erythrocyte band 3 protein. Eur J Immunol (1993) 1.08
Characterization of CD3+ CD4- CD8- (double negative) T cells in patients with systemic lupus erythematosus: production of IL-4. Lupus (2002) 1.06
Characterization of CD3+ CD4- CD8- (double negative) T cells in patients with systemic lupus erythematosus: activation markers. Lupus (2002) 1.05
CD5-expressing B lymphocytes in the blood and salivary glands of patients with primary Sjögren's syndrome. J Autoimmun (1988) 1.03
Specificity of plasma cells in the rheumatoid synovium. I. Immunoglobulin class of antiglobulin-producing cells. Scand J Immunol (1984) 1.03
TT virus sequence heterogeneity in vivo: evidence for co-infection with multiple genetic types. J Gen Virol (1999) 1.02
Recent progress in the understanding of B-cell functions in autoimmunity. Scand J Immunol (2001) 1.01
CD8+ T cells in human uterine endometrial lymphoid aggregates: evidence for accumulation of cells by trafficking. Immunology (2001) 1.01
Intradermal hepatitis B vaccine. Lancet (1987) 0.99
Idiotypes and autoimmunity. Springer Semin Immunopathol (1983) 0.98
Antibody to both human herpesvirus 6 and cytomegalovirus. Lancet (1988) 0.97
Auto- and polyreactivity of IgM from CD5+ and CD5- cord blood B cells. Scand J Immunol (1991) 0.97
Receptors for IgM are expressed on acute lymphoblastic leukemic cells having T-cell characteristics. Clin Immunol Immunopathol (1977) 0.97
A common epitope identified by a monoclonal antibody, MID 2, present on all leucocytes and associated with a group of high molecular weight glycopeptides. Scand J Immunol (1984) 0.96
Ontogeny of B cells in the chicken. II. Changing patterns of cytoplasmic IgM expression and of modulation requirements for surface IgM by anti-mu antibodies. J Immunol (1977) 0.96
1,25-Dihydroxyvitamin D3, but not retinoic acid, induces the differentiation of U937 cells. Clin Exp Immunol (1989) 0.96
Immunisation with phage displaying peptides representing single epitopes of the glycoprotein G can give rise to partial protective immunity to HSV-2. Virology (2000) 0.95
Induction of suppression through human T cell interactions. Clin Exp Immunol (1980) 0.95
The public health response to a case of Lassa fever in London in 2000. J Infect (2004) 0.95
Intradermal vaccination against hepatitis B. Lancet (1986) 0.95
Modulation of human natural killer cell activity by pharmacological mediators. Clin Exp Immunol (1983) 0.94
Delineation of chicken lymphocyte populations by specific anti-thymus and anti-bursa sera. Cell Immunol (1972) 0.93
Expansion of CD4+ T cells with a cytotoxic phenotype in patients with B-chronic lymphocytic leukaemia (B-CLL). Clin Exp Immunol (2001) 0.93
Exchanging sex for crack-cocaine: a comparison of women from rural and urban communities. J Community Health (1992) 0.93
Evidence for antibody-dependent cell-mediated cytotoxicity by T cells bearing receptors for IgG. Clin Exp Immunol (1979) 0.93
Abnormal responses of rheumatoid arthritis lymphocytes to Epstein-Barr virus infection in vitro: evidence for multiple defects. Ann Rheum Dis (1985) 0.93
Bursal origin of bone marrow cells with competence for antibody formation. Immunology (1972) 0.93
Human lymphocyte antigens: a mini review. Biochem Soc Trans (1985) 0.93
Antibody mediated regulation of immune responses. I. Enhancement of specific antibody responses through IgM antibodies. Immunol Lett (1982) 0.93
HIV-1 in semen: determination of proviral and viral titres compared to blood, and quantification of semen leukocyte populations. J Med Virol (1999) 0.92
The biggest problem in diabetes. Diabetes Educ (1986) 0.92
The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy. J Viral Hepat (2013) 0.92
In situ hybridization studies of adenoviral infections of the lung and their relationship to follicular bronchiectasis. Am Rev Respir Dis (1989) 0.92
The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus. Clin Exp Immunol (2001) 0.92
Informed consent. Study in which patients had HIV tests could have been designed differently. BMJ (1997) 0.92
Production of erythrocyte autoantibodies in NZB mice is inhibited by CD4 antibodies. Clin Exp Immunol (1994) 0.92
Familial translocation t(9;16). J Med Genet (1989) 0.91
The development of monoclonal antibodies to the human mitochondrial 60-kd heat-shock protein, and their use in studying the expression of the protein in rheumatoid arthritis. Arthritis Rheum (1992) 0.91
II. IgM-mediated enhancement: dependency on antigen dose, T-cell requirement and lack of evidence for an idiotype-related mechanism. Immunology (1983) 0.91
Evidence for B cell activation in patients with active rheumatoid arthritis. Clin Exp Immunol (1984) 0.91
Selective expression of a VHIV subfamily of immunoglobulin genes in human CD5+ B lymphocytes from cord blood. J Exp Med (1991) 0.91
Repair of chemical carcinogen-induced damage in DNA of human lymphocytes and lymphoid cell lines--studies of the kinetics of removal of O6-methylguanine and 3-methyladenine. Chem Biol Interact (1986) 0.91
Receptors for IgM on human lymphocytes. II. Mitogen-induced modulation of receptor expression. Clin Exp Immunol (1979) 0.91
Cytotoxicity of tumor necrosis factor for thyroid epithelial cells and its regulation by interferon-gamma. Eur J Immunol (1987) 0.91
Rheumatoid arthritis: how well do the theories fit the evidence? Clin Exp Immunol (1993) 0.91
Prostaglandin E2-mediated enhancement of human plasma cell differentiation. Immunol Lett (1982) 0.90
Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex. Clin Exp Immunol (2007) 0.90
Interferon-mediated enhancement of thyroid major histocompatibility complex antigen expression. A flow cytometric analysis. Scand J Immunol (1987) 0.90
Prevalence of hepatitis C antibodies among healthcare workers of two teaching hospitals. Who is at risk? BMJ (1997) 0.90
Polymorphism and expression of the galactosyltransferase-associated protein kinase gene in normal individuals and galactosylation-defective rheumatoid arthritis patients. Arthritis Rheum (1990) 0.89
Diverse antigen specificity of erythrocyte-reactive monoclonal autoantibodies from NZB mice. Clin Exp Immunol (1996) 0.89
Role of B-cell antigen receptor-associated molecules and lipid rafts in CD5-induced apoptosis of B CLL cells. Leukemia (2005) 0.89
Early regulation of c-myc mRNA by 1,25-dihydroxyvitamin D3 in human myelomonocytic U937 cells. J Mol Endocrinol (1989) 0.89
T gamma delta-cell subsets in cord and adult blood. Scand J Immunol (1990) 0.89
IgG glycosylation in autoimmune-prone strains of mice. Clin Exp Immunol (1994) 0.89
Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo. Br J Haematol (1994) 0.88
The presence of rheumatoid factor in sera from anti-HCV positive blood donors interferes with the detection of HCV-specific IgM. Trent HCV Study Group. J Hepatol (1996) 0.88
Serum HCV RNA levels assessed by quantitative NASBA: stability of viral load over time, and lack of correlation with liver disease. The Trent HCV Study Group. J Hepatol (1996) 0.88
The role of TG lymphocytes in cell-mediated immunity in patients with periodontal disease. Clin Exp Immunol (1981) 0.88
Lymphocytes from patients with rheumatoid arthritis produce agalactosylated IgG in vitro. Clin Exp Immunol (1992) 0.87
Diagnosis of acute hepatitis C virus infection and estimated incidence in low- and high-risk English populations. J Viral Hepat (2008) 0.87
Clinical features and diagnosis of 42 travellers with cutaneous leishmaniasis. Travel Med Infect Dis (2005) 0.86
Identification of type-specific domains within glycoprotein G of herpes simplex virus type 2 (HSV-2) recognized by the majority of patients infected with HSV-2, but not by those infected with HSV-1. J Gen Virol (1999) 0.86
Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management. J Viral Hepat (2007) 0.86